Found 22 matching trials
Trial of Trientine Plus Pegylated Liposomal Doxorubicin and Carboplatin in Epithelial Ovarian Cancer PHASE1 Epithelial ovarian cancer (EOC) is the leading cause of gynecological malig...
Show More Location
Multiple Locations
Learn More & Join Trial
Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine PHASE4 A study to review Wilson disease patients who have previously been prescrib...
Show More Location
Universitätsklinik Heidelberg
Learn More & Join Trial
Trientine Hydrochloride for the Prevention of Macular Edema After Cataract Surgery in Patients With Type 2 Diabetes Mellitus PHASE2 The primary purpose of the protocol is to evaluate whether Trientine Hydroc...
Show More Location
Univeristy of British Columbia/Vancouver Coastal Health Authority - Eye Care Center
Learn More & Join Trial
Trientine Hydrochloride for the Prevention of Macular Edema Associated With Pan-retinal Photocoagulation for Severe Non-proliferative and Proliferative Diabetic Retinopathy NA To evaluate the effects of Trientine Hydrochloride in prevention of post-la...
Show More Location
Eye Care Centre - Vancouver Coastal Health
Learn More & Join Trial
Off Treatment Urinary Copper Excretion in Wilson Disease, Pilot Study N/A This is a prospective study that will determine the optimal timing for 24-h...
Show More Location
Yale School of Medicine
Learn More & Join Trial
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. PHASE3 The goal of this clinical trial is to learn if a new trientine tetrahydroch...
Show More Location
University of Colorado Anschutz School of Medicine
Learn More & Join Trial
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease PHASE3 This is a multicenter, randomized, open-label study with an active standard...
Show More Location
Yale University School of Medicine
Learn More & Join Trial
Study Comparing Once Daily Dose of 900mg of TETA 4HCL Against Cuprior® (450mg Trientine Base, Twice Daily). PHASE1 A randomised, open-label study evaluating the pharmacokinetics, safety, and...
Show More Location
Richmond Pharmacology Ltd
Learn More & Join Trial
Patient Preference Study: Standard of Care Versus Once-daily Trientine Tetrahydrochloride PHASE2 Decentralized study to assess patient reported treatment satisfaction compa...
Show More Learn More & Join Trial
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment N/A This was a 24-month study to assess copper parameters in participants with ...
Show More Location
Clinical Trial Site
Learn More & Join Trial